BCL6 and B-cell non-Hodgkin lymphoma: In Ph+ ALL, light chain rearrangements are known to promote the expression of BCL6, a protein associated with survival and drug resistance [72–74], whereas in B cell lymphomas, active BCR signaling has been shown to drive tumorigenesis and support leukemia cell survival [73, 75].